Theralase Technologies Inc. V.TLT

RE:Lung cancer: BPMC shrank tumors in 60% of a specific cohort

[Claridge]

More on their NSCLC niche market:

 

Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019 | Blueprint Medicines Corp.

 

RET Rearrangements in Non-Small Cell Lung Cancer

 

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC).

_________________

Claridge - (6/19/2019 5:31:21 PM) 

Lung cancer: BPMC shrank tumors in 60% of a specific cohort

BPMC now has a market cap of 4.7B$US, its highest since May 2015.

Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array 11.4B$ Deal

As expected, there has been an accelerated pace of merger and acquisitions (M&A) activity in pharma space this year, especially in cancer. We have already seen some major deals this year. In January, Bristol-Myers offered to buy Celgene for$74 billion, followed by Lilly’s acquisition of Loxo Oncology for $8 billion in February.

Blueprint Medicines Corporation (BPMC)

With a market cap of $4.61 billion, Blueprint Medicines Corporation (BPMC) is a precision therapy company focused on genomically defined cancers and cancer immunotherapy. 

The Cambridge, Massachusetts-based company said earlier this month that its inhibitor BLU-667 shrank tumors in 60% of a difficult-to-treat group of lung cancer patients and that it's preparing for a 2020 filing in patients with RET-altered non-small cell lung cancer who had already tried chemotherapy.


Pipeline | Blueprint Medicines